UTI Healthcare Fund (Equity, Equity Sectoral-pharma)

20 yrs 8 monthsStarted on:28 Jun 1999
₹ 394.61 Cras on: 20 Jan 2020
Long Term Horizon
Capital Appreciation

Minimum Investment

  • ₹ 5000.00 for Lumpsum

Investment Objective

The scheme seeks to generate long term capital appreciation by investing predominantly in equity and equity related securities of companies/institutions engaged in the Healthcare Services Sector.

Exit Load

Scheme Documents

Similar Funds
Nippon India pharma fund
Current NAV 156.3
Return (CAGR) 19.22%
Value Research NA
SBI Healthcare Opportunities Fund
Current NAV 123.2
Return (CAGR) 14.42%
Value Research NA
TATA India Pharma & Health Care Fund
Current NAV 9.54
Return (CAGR) -1.14%
Value Research NA


TenureReturns (CAGR)
1 Month4.54
3 Month12.24
1 YR6.10
3 YR0.86

SIP Returns

TenureReturns (CAGR)
1 YR15.42
2 YR5.2
3 YR3.03
5 YR0.33
10 YR7.62


Company Name% Assets
Sun Pharmaceutical Inds. Ltd.11.33
Cipla Ltd.9.7
Divi's Laboratories Ltd.7.79
Lupin Ltd.7.02
Aurobindo Pharma Ltd.6.35
Ipca Laboratories Ltd.6.06
Dr. Reddy's Laboratories Ltd.5.88
Cadila Healthcare Ltd.5.35
Eris Lifesciences Ltd4.47
FDC Ltd.3.89

Top Sectoral Holdings

Sector Name% Assets


Portfolio turnover ratio54
Standard Deviation15.21%

V Srivatsa

Mr. Srivatsa is a B.Com (H), Chartered Accountant, CWA. and PGDM from IIM Indore.
Prior to joining UTI in 2002 he has worked with Ford, Rhodes Parks & Co., Chartered Accountants and Madras Cements Ltd.

Other Funds Managed by V Srivatsa